Summary The antibiotic drug novobiocin was evaluated for its anti-tumour properties in B16 melanoma cells. Novobiocin is shown to inhibit melanoma B 16 cell proliferation. The anti-proliferative effect was gradually reversible upon removal of novobiocin from the culture medium. Growth inhibition by novobiocin was accompanied by phenotypic alterations, that included morphological changes, lipid accumulation and marked increases in the activities of NADPH cytochrome c reductase and y glutamyl transpeptidase. In vivo administration of repeated i.p. doses of novobiocin, to mice implanted with B16 melanoma cells resulted in growth retardation. The combined treatment of the B16 melanoma cells with novobiocin and other chemical inducers of differentiation was examined in a cell growth assay. Novobiocin and sodium butyrate inhibited cell growth in a near additive manner, while combination of novobiocin with the GTP-depleting agents, tiazofurin or mycophenolic acid resulted in a synergistic decrease in cell growth. Our results support the contention further that novobiocin and other differentiating agents might be of potential value in melanoma therapy.
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Melanoma is known to be a chemotherapy-resistant cancer. Previous studies from our laboratory have focussed on the evaluation of the effects of chemical inducers of differentiation on mouse and human melanoma cells. These studies were aimed at the discovery of modalities that might modulate the cells to express a more differentiated and benign phenotype. We have shown that several agents, belonging to different chemical groups, such as dimethylsulfoxide, dimethylthiourea, sodium butyrate, histidinol and 8-hydroxyquinoline inhibit melanoma cell proliferation and induce differentiated characteristics in the cells (Nordenberg et al., 1985; 1987; . However, the compounds tested so far did not seem to be suitable for immediate clinical evaluation.
Novobiocin (Figure 1 ), a coumermycin antibiotic drug, which inhibits prokaryotic and eukaryotic DNA replication seemed to be an interesting candidate for evaluation as an anti-tumour differentiating agent in melanoma. The best known effect of novobiocin is its inhibition of topoisomerase II activity, due to interference with the ATPase subunits of the enzyme (Gellert, 1982) . Novobiocin was recently shown to induce cell differentiation in several leukaemic cell lines (Constantinou et al., 1989; Rappa et al., 1990) . Induction of differentiation in the HL-60 leukaemic cell line was attributed to inhibition of topoisomerase II activity (Constantinou et al., 1989) . Novobiocin was also reported to induce mitochondrial damage, leading to a decrease in the ATP/ADP ratio in Hela cells (Downes et al., 1985) . We have recently shown that inhibition of B16 melanoma cell growth and induction of differentiated features by dimethylthiourea was at least partially mediated by a decrease in ATP content (Fux et al., 1991) . Recent reports have also focussed interest on the anti-tumour properties of novobiocin. It was shown to exert in vitro and in vivo synergistic anti-tumour effects with alkylating agents (Eder et al., 1987; , to enhance cisplatinum cytoxicity (Eder et al., 1987; and to increase sensitivity of ovarian cancer cells to hyperthermia (Warters et al., 1988) . Recently, a phase I trial of novobiocin in combination with cyclophosphamide has been conducted in patients with various disseminated malignancies (Eder et al., 1991 (Jahangeer et al., 1982; Toshiyuki et al., 1984; Kyritsis et al., 1985) . (Nordenberg et al., 1986 (Pearse, 1968) and visualised by light microscopy. For determination of enzyme activities, cells (7 x 105) in 10 ml of culture medium were incubated for 72 h in the absence or presence of novobiocin (100 gM). NADPH cytochrome c reductase and I glutamyl transpeptidase activities were determined spectrophotometrically, as previously described (Nordenberg et al., 1987) . NADPH cytochrome c reductase activity was expressed as nmoles acceptor reduced h-' mg-' DNA. j Glutamyl transpeptidase activity was expressed as gLmoles product formed h-' mg ' DNA. DNA was measured by the fluorometric method described by Labarca and Paigen (1980) . Tumour cell inoculation and systemic administration of novobiocin 5 x 104 B16 melanoma cells were s.c. inoculated on the dorsum of the mice as previously described (Nordenberg et al., 1985) . Tumour growth was followed by measuring the tumour diameters in three dimensions, using calipers and tumour volume was calculated as previously described (Nordenberg et al., 1985) . 0.3 ml PBS with, or without novobiocin (150 mg Kg-') were injected i.p. according the following schedule: three times daily for the first 2 days after tumour cell inoculation and then twice daily for additional 10 days. (The number of daily novobiocin doses was decreased from three to two times daily because the mice suffered from diarrhoea). At 48 h 150 tLM novobiocin decreased cell number beyond initial number plated, suggesting that this concentration led to an initial reduction in cell viability. However, proliferation of remaining cells did not stop as can be seen from the 96 h data. The cells that were counted after 96 h did not detach and were 95% viable as assessed by the trypan blue exclusion test.
Effects of differentiating agents on solid tumour cell lines are known to be reversible. In order to examine whether novobiocin-treated cells resume growth following removal of novobiocin from the culture medium cells were replated without novobiocin for different time periods. The results show that 4 days following removal of novobiocin from the medium, its growth inhibitory effect was still maintained (Figure 3a) . However, growing the cells for 11 days in novobiocin-free medium, resulted in restoration of normal growth rate (Figure 3b) .
The sensitivity of cells to growth-inhibition by novobiocin in short term cultures prepared from fresh melanoma tumours was compared to that of the cells grown as a continuous cell line. Both cell types were found to be equally with sodium butyrate at a dose leading to a 40% decrease in cell number in combination with several concentrations of novobiocin resulted in a near additive growth inhibitory effect ( Figure 6 ).
The effect of combined treatment of the B16 cells with novobiocin and either tiazofurin or mycophenolic acid is depicted in Figures 7 and 8 . The combination of novobiocin with mycophenolic acid, or with tiazofurin resulted in a decrease in cell number that was greater than the expected calculated value of an additive interaction, suggesting that novobiocin and GTP-depleting agents may interact synergistically.
Discussion
Novobiocin was shown to induce anti-proliferative effects in vitro and in vivo in B16 melanoma. Growth inhibition by novobiocin was reversible and was accompanied by phenotypic alterations that resemble those induced by other differentiating agents. These included morphological changes, lipid droplet accumulation and enhancement of the activities of NADPH cytochrome c reductase and glutamyl transpeptidase. We have previously shown that this specific pattern of phenotypic alterations was induced by the well known chemical inducer of differentiation sodium butyrate in mouse and human melanoma cell lines (Nordenberg et al., 1986; 1987) . As previously suggested, the phenotypic alterations induced by the differentiating agents are at least in part compatible with a more differentiated state. The increase in NADPH cytochrome c reductase, a marker enzyme of the endoplasmic reticulum has been described to accompany the action of all chemical inducers of differentiation that produced anti-proliferative effects in melanoma cells (Fux et al., 1989) . The development of endoplasmic reticulum and the increase in its marker enzyme (NADPH cytochrome c reductase) might reflect cell differentiation, as normal melanocytic development is also accompanied by the appearance of endoplasmic reticulum and golgi complexes (Jimbo & Vesugi, 1982) . A potential role for y glutamyl transpeptidase in the synthesis of pheomelanin from 5-S-cysteinyldopa has been suggested (Mojamdar et al., 1983) . Although novobiocin did not induce a change in pigmentation similar to sodium butyrate, a marked increase in the activity of this enzyme was observed. Other melanoma differentiating agents, such as a MSH and theophylline were also reported to enhance the activity of this enzyme (Hu, 1982; Mojamdar et al., 1983) . In leukemic HL-60 cells, the differentiating effect of novobiocin was associated with a reduction in topoisomerase II activity (Constantinou et al., 1989 (Fux et al., 1991) . Several combinations of differentiating agents with sodium butyrate resulted in synergistic interactions. Novobiocin and sodium butyrate were reported to have synergistic effects on transformation of Chang liver cell into fibroblast-like cells (Kaneko et al., 1988) . These authors also found that novobiocin, similar to sodium butyrate increased nuclear protein acetylation. The combined treatment of the B16 cells with novobiocin and sodium butyrate did not result in a more than additive interaction. This may suggest that these agents act either independently on the cells, or by the same pathway.
GTP-depleting agents, such as mycophenolic acid and tiazofurin were shown to be inducers of cell differentiation in several cell types, including melanoma cells (Wright, 1987; Sidi et al., 1988) . Tiazofurin was also used in clinical trials (Weber et al., 1989) .
The mechanism for the combined synergistic interaction of novobiocin and GTP-depleting agents has not been explored so far. However, the decrease in both ATP and GTP might provide a clue to the interaction of novobiocin and the GTP-depleting agents. A methotrexate analog that depletes ATP and GTP content has recently been reported to be a potent inducer of leukaemic cell differentiation (Sokoloski et al., 1990 ).
Previous studies of Eder et al. (1987; demonstrated enhancement of the anti-tumour effects of alkylating agents in leukaemia and fibrosarcoma bearing mice. In this study an in vivo growth inhibitory effect of novobiocin was found in melanoma bearing mice.
The mechanism of in vivo growth inhibition by novobiocin is as yet unclear. The multiple targets that have been described for the action of novobiocin (Gellert, 1982; Downes et al., 1985; Lynch et al., 1976; Edenberg, 1980) , do not identify a specific mechanism. However, our data showing induction of differentiation by novobiocin in vitro may imply that phenotypic alterations occurring in vivo contribute to the observed anti-tumour effect. The present study encourages further investigation of the mechanism of the phenotypic alterations induced by novobiocin in melanoma.
Novobiocin has a profound advantage over other differentiating agents used so far, since it is a drug already used as anti-microbial chemotherapy (Drusano et al., 1986) . This fact obviously facilitated the phase I trial with novobiocin for solid tumours, including melanoma, that has recently been reported (Eder et al., 1991) .
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